<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Molecules</journal-id><journal-id journal-id-type="iso-abbrev">Molecules</journal-id><journal-id journal-id-type="publisher-id">molecules</journal-id><journal-title-group><journal-title>Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry</journal-title></journal-title-group><issn pub-type="epub">1420-3049</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6100563</article-id><article-id pub-id-type="doi">10.3390/molecules23061340</article-id><article-id pub-id-type="publisher-id">molecules-23-01340</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Role of O-Acetylation in the Immunogenicity of Bacterial Polysaccharide Vaccines</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Berti</surname><given-names>Francesco</given-names></name><xref ref-type="aff" rid="af1-molecules-23-01340">1</xref></contrib><contrib contrib-type="author"><name><surname>De Ricco</surname><given-names>Riccardo</given-names></name><xref ref-type="aff" rid="af2-molecules-23-01340">2</xref></contrib><contrib contrib-type="author"><name><surname>Rappuoli</surname><given-names>Rino</given-names></name><xref ref-type="aff" rid="af3-molecules-23-01340">3</xref><xref rid="c1-molecules-23-01340" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Kovac</surname><given-names>Paul</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Xu</surname><given-names>Peng</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Pfister</surname><given-names>Helene</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-molecules-23-01340"><label>1</label>Technical R&#x00026;D, GSK Vaccines, 53100 Siena, Italy; <email>francesco.x.berti@gsk.com</email></aff><aff id="af2-molecules-23-01340"><label>2</label>Preclinical R&#x00026;D, GSK Vaccines, 53100 Siena, Italy; <email>riccardo.x.de-ricco@gsk.com</email></aff><aff id="af3-molecules-23-01340"><label>3</label>External R&#x00026;D, GSK Vaccines, 53100 Siena, Italy</aff><author-notes><corresp id="c1-molecules-23-01340"><label>*</label>Correspondence: <email>rino.x.rappuoli@gsk.com</email>; Tel.: +39-0577-243414</corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>6</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2018</year></pub-date><volume>23</volume><issue>6</issue><elocation-id>1340</elocation-id><history><date date-type="received"><day>08</day><month>5</month><year>2018</year></date><date date-type="accepted"><day>30</day><month>5</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 by the authors.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The incidence of infectious diseases caused by several bacterial pathogens such as <italic>Haemophilus influenzae</italic> type b, <italic>Streptococcus pneumoniae</italic>, and <italic>Neisseria meningitidis</italic>, has been dramatically reduced over the last 25 years through the use of glycoconjugate vaccines. The structures of the bacterial capsular polysaccharide (CPS) antigens, extracted and purified from microbial cultures and obtained with very high purity, show that many of them are decorated by O-acetyl groups. While these groups are often considered important for the structural identity of the polysaccharides, they play a major role in the functional immune response to some vaccines such as meningococcal serogroup A and <italic>Salmonella typhi</italic> Vi, but do not seem to be important for many others, such as meningococcal serogroups C, W, Y, and type III Group B <italic>Streptococcus</italic>. This review discusses the O-acetylation status of CPSs and its role in the immunological responses of these antigens.</p></abstract><kwd-group><kwd>bacterial vaccines</kwd><kwd>conjugate vaccines</kwd><kwd>carbohydrate antigens</kwd><kwd>O-acetylation</kwd></kwd-group></article-meta></front><body><sec id="sec1-molecules-23-01340"><title>1. Introduction </title><p>Glycoconjugation is a very well established &#x02018;technology platform&#x02019; for bacterial vaccine development. Vaccines have been licensed and have strongly contributed to preventing <italic>Haemophilus influenzae</italic> type b, <italic>Streptococcus pneumoniae</italic>, and <italic>Neisseria meningitidis</italic> infections. Additional vaccines against other bacteria (e.g., Group B <italic>Streptococcus</italic>, <italic>Salmonella typhi</italic> Vi) or further <italic>Streptococcus pneumoniae</italic> and <italic>Neisseria meningitidis</italic> serogroups not included in the registered formulations are currently in clinical development [<xref rid="B1-molecules-23-01340" ref-type="bibr">1</xref>]. </p><p>Bacterial capsular polysaccharide (CPS) antigen structures, extracted and purified from microbial cultures or synthetically prepared (i.e., Quimi-Hib) [<xref rid="B2-molecules-23-01340" ref-type="bibr">2</xref>], have been deeply investigated in the last decades. Nuclear magnetic resonance (NMR) spectroscopy, which provides fingerprint-type characteristics of the structure and is sensitive to small structural differences, has played a key role in the carbohydrate structure determination [<xref rid="B3-molecules-23-01340" ref-type="bibr">3</xref>].</p><p>Bacterial polysaccharides often contain an array of substituents, such as O-acetyl and phosphate groups, which may constitute an important part of the immunodominant epitopes. CPSs from many pathogenic bacteria are O-acetylated, and a common feature is that the O-acetyl groups are easily removed at an alkaline pH. The O-acetyl content is considered an aspect of &#x02018;identity&#x02019;, as some immunologically distinguishable CPSs differ in the presence of O-acetyl groups only (e.g., pneumococcal types 9A&#x02013;9V [<xref rid="B4-molecules-23-01340" ref-type="bibr">4</xref>], and 11A&#x02013;11E [<xref rid="B5-molecules-23-01340" ref-type="bibr">5</xref>,<xref rid="B6-molecules-23-01340" ref-type="bibr">6</xref>]); the immune responses evoked by these CPSs are not necessarily cross-protective.</p><p>O-acetyl groups have been determined to be inside or outside the saccharide ring of monosaccharides constituting the repeating units of capsular polysaccharides. In <xref ref-type="fig" rid="molecules-23-01340-f001">Figure 1</xref>, the repeating unit structures of meningococcal serogroup A and C with O-acetyl groups inside or outside the saccharide ring are respectively reported.</p><p>Here we review the presence of the O-acetyl groups in capsular antigens and we try to address their role in the functional immune response.</p></sec><sec id="sec2-molecules-23-01340"><title>2. O-acetylation in Conjugate Vaccines</title><p>O-acetylation patterns have been determined for several polysaccharide antigens (<xref rid="molecules-23-01340-t001" ref-type="table">Table 1</xref>). </p><sec id="sec2dot1-molecules-23-01340"><title>2.1. Neisseria Meningitidis</title><p>The &#x003b1;-1,6-linked <italic>N</italic>-acetylmannosamine phosphate constituting the repeating unit of meningococcal serogroup A CPS is partly O-acetylated at position C<sub>3</sub> or C<sub>4</sub> (<xref rid="molecules-23-01340-t001" ref-type="table">Table 1</xref>)<sub>.</sub> The meningococcal serogroups C, W, and Y, which all contain Neu5Ac moiety in the relative repeating units, are partially O-acetylated at the glycerol chain of Neu5Ac (at positions C<sub>7</sub> and C<sub>8</sub> for serogroup C and at positions C<sub>7</sub> and C<sub>9</sub> for serogroup W and Y) [<xref rid="B7-molecules-23-01340" ref-type="bibr">7</xref>] (<xref rid="molecules-23-01340-t001" ref-type="table">Table 1</xref>). The meningococcal genes coding O-acetylation of various serogroups have been analyzed [<xref rid="B8-molecules-23-01340" ref-type="bibr">8</xref>]. On the contrary, the meningococcal serogroup X CPS [&#x02192;4)-&#x003b1;-<sc>d</sc>-Glc<italic>p</italic>NAc-(1&#x02192;OPO<sub>3</sub>&#x02192;] is not O-acetylated [<xref rid="B9-molecules-23-01340" ref-type="bibr">9</xref>,<xref rid="B10-molecules-23-01340" ref-type="bibr">10</xref>]. </p><p>The meningococcal serogroup A plain CPS is largely O-acetylated at position C<sub>3</sub> (&#x0003e;90%) and slightly at position C<sub>4</sub> [<xref rid="B11-molecules-23-01340" ref-type="bibr">11</xref>,<xref rid="B12-molecules-23-01340" ref-type="bibr">12</xref>] (<xref ref-type="fig" rid="molecules-23-01340-f001">Figure 1</xref>a). MynC was identified as new subclass of O-acetyltransferases that utilize acetyl-CoA to decorate the serogroup A CPS. Although a single or dual specificity of MynC (at positions C<sub>3</sub> and/or C<sub>4</sub>) has not been demonstrated, the single specificity and a spontaneous migration of the O-acetyl group from the site of attachment around the ring is, perhaps, a more likely explanation. While a study demonstrated that O-acetylation is not required for capsule expression or to protect the meningococci from killing by normal human sera, investigation with O-acetylation-deficient mutant confirmed the importance of O-acetylation in serogroup A polysaccharide immunogenicity [<xref rid="B11-molecules-23-01340" ref-type="bibr">11</xref>,<xref rid="B13-molecules-23-01340" ref-type="bibr">13</xref>,<xref rid="B14-molecules-23-01340" ref-type="bibr">14</xref>]. Berry et al. [<xref rid="B15-molecules-23-01340" ref-type="bibr">15</xref>] confirmed that serogroup A-specific antibodies elicited in post-immunization human sera mostly identified O-acetylated CPS residues, impacting the degree of antibody inhibition. Comparative immunogenicity studies in mice revealed that de-O-acetylated antigens resulted in a marked loss of immunogenicity (total IgG), and, most relevantly, a loss in their ability to induce functional bactericidal antibodies. However, epitopes not involving O-acetyl groups may also contribute to the development of protective response since mice vaccinated with de-O-acetylated antigens elicited some functional antibodies.</p><p>In a phase III partially blinded, controlled study (where 1170 healthy subjects aged 18 to 25 years were randomized (1:1:1)), two lots of meningococcal ACWY-tetanus toxoid conjugate vaccines (MenACWY-TT) that differed in serogroup A CPS O-acetylation levels respectively (68% vs. 92% O-acetylation), were evaluated in terms of immunogenicity (i.e., rabbit serum bactericidal activity (rSBA)) and safety in comparison to a licensed MenACWY CPS vaccine (82% serogroup A O-acetylation). The MenA-TT conjugate with O-acetylation levels of 68% and 92% resulted in comparable vaccine immunogenicity [<xref rid="B16-molecules-23-01340" ref-type="bibr">16</xref>]. As a matter of fact, all the meningococcal serogroup A conjugate contained in licensed vaccines (MenAfriVac&#x02013;Serum Indian Institute; Menveo&#x02013;GSK Vaccines; Menactra&#x02013;Sanofi Pasteur; Nimenrix&#x02013;GSK Vaccines (later taken over by Pfizer)) are largely O-acetylated. However, no evidence has been collected to define the minimal O-acetylation level affecting the immunogenicity of meningococcal serogroup A vaccines for the moment.</p><p>The high relevance of the O-acetyl moieties for serogroup A <italic>N. meningitidis</italic> could also be related to the presence of this decorative group within the saccharide ring, probably influencing and specifying the epitope in a unique arrangement that could not be easily mimicked in its absence.</p><p>Alternatively, the meningococcal serogroup C CPS is highly O-acetylated (&#x0003e;90%) at positions C<sub>8</sub> and C<sub>7</sub> of the sialic acid glycerol chain (out of the ring) (<xref ref-type="fig" rid="molecules-23-01340-f001">Figure 1</xref>b). The <italic>oatC</italic> gene required for O-acetylation of sialic acid residue was identified [<xref rid="B8-molecules-23-01340" ref-type="bibr">8</xref>]. In meningococcal C CPSs freshly extracted or not exposed to chemical conditions (i.e., basic pH), which facilitates the migration from/to vicinal hydroxyl groups (i.e., at C<sub>8</sub> and C<sub>7</sub>), most of the O-acetylation exists at position C<sub>8</sub> with fewer CPSs repeating O-acetylation at C<sub>7</sub>, or results de-O-acetylated. After migration, most of the O-acetyl groups relocate from C<sub>8</sub> to C<sub>7</sub>, leading to an epitope that is conformationally related, but not identical, to one contained in the fully de-O-acetylated serogroup C CPS. As demonstrated by Michon et al. [<xref rid="B17-molecules-23-01340" ref-type="bibr">17</xref>] the immunogenicity in mice vaccinated with partially or completely de-O-acetylated serogroup C CPS antigens, obtained by mild basic treatment of the antigens, results in higher SBA titers toward the O-acetylated serogroup C strain C11. This strain was the dominant one for the de-O-acetylated antigen during the late 1990s in the UK. However, clinical data confirmed that both O-acetylated (Menjugate, Menveo, Menitorix, Menhibrix&#x02013;GSK Vaccines; Menactra&#x02013;Sanofi Pasteur; Nimenrix&#x02013;Pfizer) and de-O-acetylated (NeisVac&#x02013;North American Vaccine Inc., later taken over by Baxter Bioscience) conjugates were very immunogenic and efficacious in large vaccination campaigns [<xref rid="B18-molecules-23-01340" ref-type="bibr">18</xref>,<xref rid="B19-molecules-23-01340" ref-type="bibr">19</xref>,<xref rid="B20-molecules-23-01340" ref-type="bibr">20</xref>,<xref rid="B21-molecules-23-01340" ref-type="bibr">21</xref>] independent of the used carrier protein (TT, DT, CRM<sub>197</sub>). The high immunogenicity did not directly correlate to the C<sub>7</sub> and C<sub>8</sub> O-acetylation in meningococcal serogroup C. This differs from the serogroup A in which the O-acetylation seems to be determinant in the immunoresponse. This lack of correlation might be related to the positions of the O-acetyl groups which are located in the glycerol chain outside the saccharide ring where the influence on the epitope could be lower. </p><p>For meningococcal W and Y CPSs, minimal O-acetylation levels have been also revealed at positions C<sub>7</sub> and C<sub>9</sub> of sialic acid moieties of several strains. As suggested by Fusco et al. [<xref rid="B22-molecules-23-01340" ref-type="bibr">22</xref>], for the meningococcal Y CPSs the O-acetyl is likely present on the surface of the organism and it seems to display significant conformational differences around its sialic acid linkages. This is not the same for the glycosidic bond between C<sub>6</sub> glucose and C<sub>2</sub> sialic acid, which does not seem to be affected by the O-acetylation status of the sialic acid. Furthermore, the authors proposed that conformational differences around the sialic acid bond between the C<sub>7</sub> and C<sub>9</sub> O-acetylated forms could be explained by the fact that the O-acetyl located at C<sub>7</sub>, in addition to the linkage at C<sub>4</sub>, influences the rotation of the sialic acid glycosidic bonds. One the other hand, the O-acetyl at C<sub>9</sub>, being away from these two centers, has no influence on the rotation (torsional angle), which therefore allows the conformational identity between C<sub>9</sub> O-acetylated and de-O-acetylated forms of Y CPSs. The preferred position of the O-acetyl group on C<sub>9</sub> Neu5Ac, which has been detected as most abundant form after purification of both meningococcal W and Y CPSs [<xref rid="B12-molecules-23-01340" ref-type="bibr">12</xref>], might arise from its higher thermodynamic stability and as a consequence of the migration of O-acetyl group from the C<sub>7</sub> to C<sub>9</sub> positions. </p><p>Although the natural occurrence of both O-acetylated and non-O-acetylated W and Y isolates has been demonstrated (i.e., in the UK with a predominance of non-O-acetylated W and O-acetylated Y strains [<xref rid="B23-molecules-23-01340" ref-type="bibr">23</xref>], and during the Hajj outbreak where all the W strains were non-O-acetylated [<xref rid="B24-molecules-23-01340" ref-type="bibr">24</xref>]), the currently licensed serogroup W and Y conjugate vaccines contain the O-acetylated CPS. The general role of O-acetylation of these CPSs is still debated, however several studies conducted in the preclinical stage and using human sera seem to confirm that there is no difference in functional activity of O-acetylated or non-O-acetylated CPSs [<xref rid="B22-molecules-23-01340" ref-type="bibr">22</xref>,<xref rid="B25-molecules-23-01340" ref-type="bibr">25</xref>,<xref rid="B26-molecules-23-01340" ref-type="bibr">26</xref>,<xref rid="B27-molecules-23-01340" ref-type="bibr">27</xref>]. By investigating the meningococcal Y antigen, Fusco et al. [<xref rid="B22-molecules-23-01340" ref-type="bibr">22</xref>] suggested that the O-acetyl groups may mask an important epitope to the immune system and thereby mislead the antibody response, resulting in an escape mechanism. Similar to meningococcal serogroup C, the O-acetylation in serogroup W and Y is outside the saccharide ring. It might confirm the poor immunological impact of this group when positioned outside the saccharide ring. However, the relatively low level of O-acetylation of several meningococcal serogroup W and Y strain might also explain the poor impact.</p></sec><sec id="sec2dot2-molecules-23-01340"><title>2.2. <italic>Group B</italic> Streptococcus</title><p>O-acetylation patterns at the &#x02018;glycerol chain&#x02019; of the Neu5Ac residue, present at the terminal end of the branch, were also confirmed for several Group B <italic>Streptococcus</italic> (GBS) CPS serotypes (Ia, Ib, II, III, V, and VI) (<xref rid="molecules-23-01340-t001" ref-type="table">Table 1</xref>), and were demonstrated to affect the inhibition of neutrophil suppression and virulence [<xref rid="B28-molecules-23-01340" ref-type="bibr">28</xref>,<xref rid="B29-molecules-23-01340" ref-type="bibr">29</xref>,<xref rid="B30-molecules-23-01340" ref-type="bibr">30</xref>]. Data were consistent with an initial O-acetylation at position C<sub>7</sub>, and subsequent migration of the O-acetyl ester at positions C<sub>8</sub> and C<sub>9</sub>. As for mammalian glycoproteins, O-acetylation of terminal sialic acid is a mechanism to prevent enzymatic de-sialylation; the exposure of terminal galactose and its excretion from the animal allow for speculation on a similar attitude of GBS.</p><p>Sera from healthy adults immunized with de-O-acetylated GBS CPS-TT conjugate vaccines were evaluated in opsonophagocytosis assays using 20 GBS clinical isolates (type Ia, Ib, II, III, or V CPSs with O-acetylation levels ranging from 2 to 40%). The data showed &#x0003e;90% opsonophagocytosis and killing of all strains, confirming that de-O-acetylated CPS-conjugate vaccines contain immunogenic epitopes that offer protection against GBS, independent of O-acetyl CPS modifications. Thus, presence of O-acetyl groups on the GBS CPSs is not essential for functional antibodies to be elicited by GBS glycoconjugate vaccines [<xref rid="B31-molecules-23-01340" ref-type="bibr">31</xref>]. In the work of Carboni et al. the structure of a protective epitope of the group B <italic>Streptococcus</italic> type III capsular polysaccharide was investigated. The authors observed that the mAb interacts with the O<sub>7</sub> of sialic acid through an H<sub>2</sub>O molecule, and dimensionally, this space could also host an acetyl group [<xref rid="B32-molecules-23-01340" ref-type="bibr">32</xref>]. This could explain data in the literature reporting that O-acetylation does not interfere with protection. </p></sec><sec id="sec2dot3-molecules-23-01340"><title>2.3. Streptococcus Pneumoniae</title><p>The presence of O-acetyl groups has been observed in several <italic>S. pneumoniae</italic> CPSs (<xref rid="molecules-23-01340-t001" ref-type="table">Table 1</xref>) but in only some has the potential role of O-acetylation been explored. A comparative study conducted both in the infant rhesus monkey model and in humans confirmed that antibodies against the de-O-acetylated backbone as well as against the O-acetylated serotype 9V CPS (O-acetyl groups revealed at positions C<sub>2</sub> and C<sub>3</sub> of the Glc residue and at positions C<sub>4</sub> and C<sub>6</sub> of the Man<italic>p</italic>NAc residue) [<xref rid="B33-molecules-23-01340" ref-type="bibr">33</xref>,<xref rid="B34-molecules-23-01340" ref-type="bibr">34</xref>] were detected. On the other hand, opsonophagocytic functional activity was observed in antisera in which the predominant antibody species recognize the de-O-acetylated serotype 9V CPS. The authors concluded that the O-acetylation side groups, while being recognized, were not essential to the ability of the serotype 9V CPS to elicit a functional antibody response [<xref rid="B34-molecules-23-01340" ref-type="bibr">34</xref>].</p><p>For the serotype 18C CPS, which contains O-acetyl groups at position C<sub>6</sub> of Glc residue in the branch [<xref rid="B35-molecules-23-01340" ref-type="bibr">35</xref>], the role of O-acetylation was explored by using rabbit and human sera. No differences were shown in inhibition curves between any of the analyzed sera and CPSs with different degrees of O-acetylation [<xref rid="B36-molecules-23-01340" ref-type="bibr">36</xref>].</p></sec><sec id="sec2dot4-molecules-23-01340"><title>2.4. Salmonella Typhi <italic>Vi</italic></title><p>The &#x003b1;-1,4-linked <italic>N</italic>-acetylgalacturonic acid constituting the repeating unit of <italic>Salmonella typhi</italic> Vi CPS is partly O-acetylated (60&#x02013;90%) at position C<sub>3</sub> (<xref rid="molecules-23-01340-t001" ref-type="table">Table 1</xref>)<sub>.</sub> The O-acetylation level is one of the critical determinants of immunogenicity in the Vi polysaccharide antigen. Removal of O-acetyl groups resulted in a lower vaccine immunogenicity [<xref rid="B37-molecules-23-01340" ref-type="bibr">37</xref>,<xref rid="B38-molecules-23-01340" ref-type="bibr">38</xref>]. </p><p>The molecular model of a pentamer (five repeating units) showed that the bulky nonpolar O-acetyl groups at position C<sub>3</sub> make up most of the surface of Vi CPS by protruding on both sides. The O-acetyl groups dominate the surface of Vi CPS and it might explain their relevant influence on its immunogenicity [<xref rid="B39-molecules-23-01340" ref-type="bibr">39</xref>].</p></sec><sec id="sec2dot5-molecules-23-01340"><title>2.5. Staphylococcus Aureus</title><p>Both <italic>S. aureus</italic> type 5 and 8 CPSs contain Man<italic>p</italic>NAcA and L- and D-Fuc<italic>p</italic>NAc residues (<xref rid="molecules-23-01340-t001" ref-type="table">Table 1</xref>). The two CPSs differ in the stereochemical glycosidic linkages between the monosaccharides constituting the repeating units and the site of O-acetylation. The sites of O-acetylation are at the position C<sub>3</sub> of L-Fuc<italic>p</italic>NAc for type 5 and at the position C<sub>4</sub> of <sc>d</sc>-Man<italic>p</italic>NAcA type 8 [<xref rid="B40-molecules-23-01340" ref-type="bibr">40</xref>]. </p><p>As confirmed by Scully et al. [<xref rid="B41-molecules-23-01340" ref-type="bibr">41</xref>] by collecting in vivo (mouse model) and in vitro experiments, the O-acetylation is necessary for CPS-CRM<sub>197</sub> conjugates to induce effective opsonophagocytic killing responses. This data supports the high importance of a careful monitoring of the degree of O-acetylation during vaccine development and production. </p><p>The authors suggested that this finding may provide additional insight into the previous failure of a <italic>S. aureus</italic> CPS conjugate vaccine. Clashing with a previous clinical trial conducted in a similar population, which suggested short-term efficacy (up to 40 weeks) against <italic>S. aureus</italic> bacteremia after a single dose of a bivalent vaccine [<xref rid="B42-molecules-23-01340" ref-type="bibr">42</xref>] (StaphVAX&#x02013;Nabi; CPS types 5 and 8 conjugated with <italic>Pseudomonas aeruginosa</italic> exotoxin A) [<xref rid="B43-molecules-23-01340" ref-type="bibr">43</xref>], a larger Phase III study failed despite robust antibody responses to primary vaccination. There was no demonstrative vaccine efficacy in preventing <italic>S. aureus</italic> bacteremia in end-stage renal disease patients receiving hemodialysis at any time interval studied or in any strategy considered [<xref rid="B44-molecules-23-01340" ref-type="bibr">44</xref>]. There has been speculation on the reasons behind this failure [<xref rid="B41-molecules-23-01340" ref-type="bibr">41</xref>,<xref rid="B44-molecules-23-01340" ref-type="bibr">44</xref>]. Issues in the manufacturing consistency of the Phase III clinical trial material have been considered due to changes in contract facilities used, although the specific impacts of these changes were not further explained. Access to the material used in the phase 3 study, for instance to detect the potentially important critical quality attributes such as O-acetylation status, would be useful for a direct comparison with earlier results and to further correlate those data with recent evidence collected in the preclinical model [<xref rid="B42-molecules-23-01340" ref-type="bibr">42</xref>]. </p></sec></sec><sec id="sec3-molecules-23-01340"><title>3. Conclusions and Future Perspectives</title><p>The O-acetyl content of CPSs so far has not been considered an attribute to be monitored for quality control in the manufacturing of glycoconjugate vaccines. Therefore, content in vaccines may vary for several reasons, including the potential release of O-acetyl groups over time in solution because the group is labile in certain conditions (preferentially in a basic environment or as a consequence of repeated freeze and thawing). Also, variety in the initial content which may be attributed to different growth conditions and manufacturing processes (i.e., different manufacturers and lot-to-lot consistency).</p><p>By summarizing the available literature data around O-acetylation, a common driver could be speculated upon: for those antigens comprised of a repetition of single or few saccharide repeating units (e.g., meningococcal serogroup A, <italic>Staphylococcus</italic> types 5 and 8), the position and the role of the O-acetyl group weighs more on the overall structure due to the fact that the epitope might be involved in the repetition of the same saccharide. On the other hand, as confirmed by data available on meningococcal serogroup C, Y or Group B <italic>Streptococcus</italic> type III antigens, where the O-acetyl group is located on a &#x02019;glycerol&#x02019; chain out of the ring positions, its presence seems to be less relevant to the immunological response. This could also explain why a migration to vicinal sites of the O-acetyl group (e.g., in C<sub>7</sub> from C<sub>8</sub> of meningococcal serogroup C CPS) does not influence the immunoresponse.</p><p>Although the position of O-acetyl group is inside or outside the saccharide ring, its distribution and population in terms of percentage of O-acetylated portions should always be considered as a critical quality attribute for a candidate vaccine.</p><p>In several cases, including meningococcal serogroup A and pneunomococcal serotype 1, the presence of the O-acetyl groups prevents periodate oxidation and reductive amination coupling as a manufacturing strategy for the glycoconjugates. Controlled de-O-acetylation is required to produce vaccines by this route (e.g., MenAfriVac, Serum Institute India, PATH). For this reason, the O-acetylation pattern also may influence the choice of manufacturing strategy.</p><p>The O-acetyl content of CPSs has been historically determined by the Hestrin colorimetric assay [<xref rid="B45-molecules-23-01340" ref-type="bibr">45</xref>]. However, during the last 15&#x02013;20 years new advanced methods that are sufficiently sensitive and based on nuclear magnetic resonance (NMR) spectroscopy [<xref rid="B12-molecules-23-01340" ref-type="bibr">12</xref>,<xref rid="B46-molecules-23-01340" ref-type="bibr">46</xref>,<xref rid="B47-molecules-23-01340" ref-type="bibr">47</xref>] or anion exchange chromatography coupled with conductivity detection (HPAEC-CD) [<xref rid="B48-molecules-23-01340" ref-type="bibr">48</xref>] have been developed. While colorimetric assay and HPAEC-CD provides an overall estimation of O-acetyl content, NMR assay developed for meningococcal CPSs [<xref rid="B12-molecules-23-01340" ref-type="bibr">12</xref>] also provides a precise distribution of the O-acetyl content at the different saccharide positions. For antigens eliciting an immune response dependent upon the O-acetyl status, it is considered as a key stability attribute which should be monitored carefully. </p><p>As reported by Jones et al. [<xref rid="B46-molecules-23-01340" ref-type="bibr">46</xref>] and Lemercinier et al. [<xref rid="B47-molecules-23-01340" ref-type="bibr">47</xref>], the kinetics of O-acetyl group release following a basic treatment with 0.2 M NaOD, which might be an indicator of its stability in aqueous solution, resulted more rapid (typically 20 min after NaOD addition) for meningococcal serogroups A, W, and Y, while it appeared slower for meningococcal serogroup C (the sample was typically incubated at 37&#x000b0;C for 1 h for complete de-O-acetylation) and for <italic>Salmonella typhi</italic> Vi CPSs, and also showed that with a 0.05 M final base concentration, the progress of de-O-acetylation could be followed in the spectrometer (narrowing of the CPS NMR peaks). </p><p>In conclusion, today we have tools to perform precise quantitative measurements of O-acetyl content in CPSs, and we should consider it a fundamental attribute to be monitored for quality control. However, each bacterial polysaccharide antigen should be considered and analyzed independently due to the intrinsic behavior that each one can exhibit. As shown for the selected bacterial polysaccharide antigens (<italic>Neisseria meningitidis</italic>, Group B <italic>Streptococcus</italic>, <italic>Streptococcus pneumoniae</italic>, <italic>Salmonella typhi</italic> Vi <italic>and Staphylococcus aureus</italic>) that have been used in licensed vaccines or vaccine clinical trials, data in the literature strongly demonstrate the fundamental role of the O-acetyl moieties influencing the immune response and, in some cases, imposing a different conformational epitope.</p><p>In the future, the ability to determine the crystal structure of protective epitopes [<xref rid="B32-molecules-23-01340" ref-type="bibr">32</xref>] combined with the possibility of preparing synthetic conjugate vaccines and the precision of analytical tools such as NMR will allow for a better understanding of the role of O-acetyl groups in glycoconjugate vaccines.</p></sec></body><back><fn-group><fn><p><bold>Sample Availability:</bold> Not available.</p></fn></fn-group><notes><title>Author Contributions</title><p>F.B., R.D.R., and R.R. wrote the paper. </p></notes><notes><title>Funding</title><p>This research received no external funding.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>F.B, R.D.R. and R.R. are employees of the GSK companies. F.B. and R.R. are owners of patents on related topics.</p></notes><ref-list><title>References</title><ref id="B1-molecules-23-01340"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vella</surname><given-names>M.</given-names></name><name><surname>Pace</surname><given-names>D.</given-names></name></person-group><article-title>Glycoconjugate vaccines: An update</article-title><source>Expert Opin. Biol. Ther.</source><year>2015</year><volume>15</volume><fpage>529</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1517/14712598.2015.993375</pub-id><?supplied-pmid 25496172?><pub-id pub-id-type="pmid">25496172</pub-id></element-citation></ref><ref id="B2-molecules-23-01340"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costantino</surname><given-names>P.</given-names></name><name><surname>Rappuoli</surname><given-names>R.</given-names></name><name><surname>Berti</surname><given-names>F.</given-names></name></person-group><article-title>The design of semi-synthetic and synthetic glycoconjugate vaccines</article-title><source>Expert Opin. Drug Discov.</source><year>2011</year><volume>6</volume><fpage>1045</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1517/17460441.2011.609554</pub-id><?supplied-pmid 22646863?><pub-id pub-id-type="pmid">22646863</pub-id></element-citation></ref><ref id="B3-molecules-23-01340"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>C.</given-names></name></person-group><article-title>NMR assays for carbohydrate-based vaccines</article-title><source>J. Pharm. Biomed. Anal.</source><year>2005</year><volume>38</volume><fpage>840</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1016/j.jpba.2005.01.044</pub-id><?supplied-pmid 16087046?><pub-id pub-id-type="pmid">16087046</pub-id></element-citation></ref><ref id="B4-molecules-23-01340"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calix</surname><given-names>J.J.</given-names></name><name><surname>Saad</surname><given-names>J.S.</given-names></name><name><surname>Brady</surname><given-names>A.M.</given-names></name><name><surname>Nahm</surname><given-names>M.H.</given-names></name></person-group><article-title>Structural characterization of <italic>Streptococcus pneumoniae</italic> serotype 9A capsule polysaccharide reveals role of glycosyl 6-O-acetyltransferase wcjE in serotype 9V capsule biosynthesis and immunogenicity</article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><fpage>13996</fpage><lpage>14003</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.346924</pub-id><?supplied-pmid 22367197?><pub-id pub-id-type="pmid">22367197</pub-id></element-citation></ref><ref id="B5-molecules-23-01340"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calix</surname><given-names>J.J.</given-names></name><name><surname>Brady</surname><given-names>A.M.</given-names></name><name><surname>Du</surname><given-names>V.Y.</given-names></name><name><surname>Saad</surname><given-names>J.S.</given-names></name><name><surname>Nahm</surname><given-names>M.H.</given-names></name></person-group><article-title>Spectrum of pneumococcal serotype 11A variants results from incomplete loss of capsule O-acetylation</article-title><source>J. Clin. Microbiol.</source><year>2014</year><volume>52</volume><fpage>758</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.1128/JCM.02695-13</pub-id><?supplied-pmid 24352997?><pub-id pub-id-type="pmid">24352997</pub-id></element-citation></ref><ref id="B6-molecules-23-01340"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camilli</surname><given-names>R.</given-names></name><name><surname>Spencer</surname><given-names>B.L.</given-names></name><name><surname>Moschioni</surname><given-names>M.</given-names></name><name><surname>Pinto</surname><given-names>V.</given-names></name><name><surname>Berti</surname><given-names>F.</given-names></name><name><surname>Nahm</surname><given-names>M.H.</given-names></name><name><surname>Pantosti</surname><given-names>A.</given-names></name></person-group><article-title>Identification of <italic>Streptococcus pneumoniae</italic> serotype 11E, serovariant 11Av and mixed populations by high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and flow cytometric serotyping assay (FCSA)</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e100722</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0100722</pub-id><pub-id pub-id-type="pmid">24967818</pub-id></element-citation></ref><ref id="B7-molecules-23-01340"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>C.</given-names></name></person-group><article-title>Vaccines based on the cell surface carbohydrates of pathogenic bacteria</article-title><source>An. Acad. Bras. Cienc.</source><year>2005</year><volume>77</volume><fpage>293</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1590/S0001-37652005000200009</pub-id><?supplied-pmid 15895165?><pub-id pub-id-type="pmid">15895165</pub-id></element-citation></ref><ref id="B8-molecules-23-01340"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claus</surname><given-names>H.</given-names></name><name><surname>Borrow</surname><given-names>R.</given-names></name><name><surname>Achtman</surname><given-names>M.</given-names></name><name><surname>Morelli</surname><given-names>G.</given-names></name><name><surname>Kantelberg</surname><given-names>C.</given-names></name><name><surname>Longworth</surname><given-names>E.</given-names></name><name><surname>Frosch</surname><given-names>M.</given-names></name><name><surname>Vogel</surname><given-names>U.</given-names></name></person-group><article-title>Genetics of capsule O-acetylation in serogroup C, W-135 and Y meningococci</article-title><source>Mol. Microbiol.</source><year>2004</year><volume>51</volume><fpage>227</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.2003.03819.x</pub-id><?supplied-pmid 14651624?><pub-id pub-id-type="pmid">14651624</pub-id></element-citation></ref><ref id="B9-molecules-23-01340"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bundle</surname><given-names>D.R.</given-names></name><name><surname>Smith</surname><given-names>I.C.</given-names></name><name><surname>Jennings</surname><given-names>H.J.</given-names></name></person-group><article-title>Determination of the structure and conformation of bacterial polysaccharides by carbon 13 nuclear magnetic resonance. Studies on the group-specific antigens of <italic>Neisseria meningitidis</italic> serogroups A and X</article-title><source>J. Biol. Chem.</source><year>1974</year><volume>249</volume><fpage>2275</fpage><lpage>2281</lpage><?supplied-pmid 4206552?><pub-id pub-id-type="pmid">4206552</pub-id></element-citation></ref><ref id="B10-molecules-23-01340"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Br&#x000f6;ker</surname><given-names>M.</given-names></name><name><surname>Berti</surname><given-names>F.</given-names></name><name><surname>Costantino</surname><given-names>P.</given-names></name></person-group><article-title>Factors contributing to the immunogenicity of meningococcal conjugate vaccines</article-title><source>Hum. Vaccin. Immunother.</source><year>2016</year><volume>12</volume><fpage>1808</fpage><lpage>1824</lpage><pub-id pub-id-type="doi">10.1080/21645515.2016.1153206</pub-id><?supplied-pmid 26934310?><pub-id pub-id-type="pmid">26934310</pub-id></element-citation></ref><ref id="B11-molecules-23-01340"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gudlavalleti</surname><given-names>S.K.</given-names></name><name><surname>Datta</surname><given-names>A.K.</given-names></name><name><surname>Tzeng</surname><given-names>Y.L.</given-names></name><name><surname>Noble</surname><given-names>C.</given-names></name><name><surname>Carlson</surname><given-names>R.W.</given-names></name><name><surname>Stephens</surname><given-names>D.S.</given-names></name></person-group><article-title>The <italic>Neisseria meningitidis</italic> serogroup A capsular polysaccharide O-3 and O-4 acetyltransferase</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>42765</fpage><lpage>42773</lpage><pub-id pub-id-type="doi">10.1074/jbc.M313552200</pub-id><?supplied-pmid 15294916?><pub-id pub-id-type="pmid">15294916</pub-id></element-citation></ref><ref id="B12-molecules-23-01340"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardotti</surname><given-names>A.</given-names></name><name><surname>Averani</surname><given-names>G.</given-names></name><name><surname>Berti</surname><given-names>F.</given-names></name><name><surname>Berti</surname><given-names>S.</given-names></name><name><surname>Carinci</surname><given-names>V.</given-names></name><name><surname>D&#x02019;Ascenzi</surname><given-names>S.</given-names></name><name><surname>Fabbri</surname><given-names>B.</given-names></name><name><surname>Giannini</surname><given-names>S.</given-names></name><name><surname>Giannozzi</surname><given-names>A.</given-names></name><name><surname>Magagnoli</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>2284</fpage><lpage>2296</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.01.022</pub-id><?supplied-pmid 18378363?><pub-id pub-id-type="pmid">18378363</pub-id></element-citation></ref><ref id="B13-molecules-23-01340"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>O.B.</given-names></name><name><surname>Claus</surname><given-names>H.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Bennett</surname><given-names>J.S.</given-names></name><name><surname>Bratcher</surname><given-names>H.B.</given-names></name><name><surname>Jolley</surname><given-names>K.A.</given-names></name><name><surname>Corton</surname><given-names>C.</given-names></name><name><surname>Care</surname><given-names>R.</given-names></name><name><surname>Poolman</surname><given-names>J.T.</given-names></name><name><surname>Zollinger</surname><given-names>W.D.</given-names></name><etal/></person-group><article-title>Description and nomenclature of <italic>Neisseria meningitidis</italic> capsule locus</article-title><source>Emerg. Infect. Dis.</source><year>2013</year><volume>19</volume><fpage>566</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.3201/eid1904.111799</pub-id><?supplied-pmid 23628376?><pub-id pub-id-type="pmid">23628376</pub-id></element-citation></ref><ref id="B14-molecules-23-01340"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fiebig</surname><given-names>T.</given-names></name><name><surname>Freiberger</surname><given-names>F.</given-names></name><name><surname>Pinto</surname><given-names>V.</given-names></name><name><surname>Romano</surname><given-names>M.R.</given-names></name><name><surname>Black</surname><given-names>A.</given-names></name><name><surname>Litschko</surname><given-names>C.</given-names></name><name><surname>Bethe</surname><given-names>A.</given-names></name><name><surname>Yashunsky</surname><given-names>D.</given-names></name><name><surname>Adamo</surname><given-names>R.</given-names></name><name><surname>Nikolaev</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Molecular cloning and functional characterization of components of the capsule biosynthesis complex of <italic>Neisseria meningitidis</italic> serogroup A: toward in vitro vaccine production</article-title><source>J. Biol. Chem.</source><year>2014</year><volume>289</volume><fpage>19395</fpage><lpage>19407</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.575142</pub-id><?supplied-pmid 24849599?><pub-id pub-id-type="pmid">24849599</pub-id></element-citation></ref><ref id="B15-molecules-23-01340"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>D.S.</given-names></name><name><surname>Lynn</surname><given-names>F.</given-names></name><name><surname>Lee</surname><given-names>C.H.</given-names></name><name><surname>Frasch</surname><given-names>C.E.</given-names></name><name><surname>Bash</surname><given-names>M.C.</given-names></name></person-group><article-title>Effect of O acetylation of <italic>Neisseria meningitidis</italic> serogroup A capsular polysaccharide on development of functional immune responses</article-title><source>Infect. Immun.</source><year>2002</year><volume>70</volume><fpage>3707</fpage><lpage>3713</lpage><pub-id pub-id-type="doi">10.1128/IAI.70.7.3707-3713.2002</pub-id><?supplied-pmid 12065513?><pub-id pub-id-type="pmid">12065513</pub-id></element-citation></ref><ref id="B16-molecules-23-01340"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lupisan</surname><given-names>S.</given-names></name><name><surname>Limkittikul</surname><given-names>K.</given-names></name><name><surname>Sosa</surname><given-names>N.</given-names></name><name><surname>Chanthavanich</surname><given-names>P.</given-names></name><name><surname>Bianco</surname><given-names>V.</given-names></name><name><surname>Baine</surname><given-names>Y.</given-names></name><name><surname>Van der Wielen</surname><given-names>M.</given-names></name><name><surname>Miller</surname><given-names>J.M.</given-names></name></person-group><article-title>Meningococcal polysaccharide A O-acetylation levels do not impact the immunogenicity of the quadrivalent meningococcal tetanus toxoid conjugate vaccine: results from a randomized, controlled phase III study of healthy adults aged 18 to 25 years</article-title><source>Clin. Vaccine Immunol.</source><year>2013</year><volume>20</volume><fpage>1499</fpage><lpage>1507</lpage><pub-id pub-id-type="doi">10.1128/CVI.00162-13</pub-id><?supplied-pmid 23885033?><pub-id pub-id-type="pmid">23885033</pub-id></element-citation></ref><ref id="B17-molecules-23-01340"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michon</surname><given-names>F.</given-names></name><name><surname>Huang</surname><given-names>C.H.</given-names></name><name><surname>Farley</surname><given-names>E.K.</given-names></name><name><surname>Hronowski</surname><given-names>L.</given-names></name><name><surname>Fusco</surname><given-names>P.C.</given-names></name></person-group><article-title>Structure activity studies on group C meningococcal polysaccharide-protein conjugate vaccines: Effect of O-acetylation on the nature of the protective epitope</article-title><source>Dev. Biol. (Basel)</source><year>2000</year><volume>103</volume><fpage>151</fpage><lpage>160</lpage><?supplied-pmid 11214233?><pub-id pub-id-type="pmid">11214233</pub-id></element-citation></ref><ref id="B18-molecules-23-01340"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vodopija</surname><given-names>I.</given-names></name><name><surname>Baklaic</surname><given-names>Z.</given-names></name><name><surname>Hauser</surname><given-names>P.</given-names></name><name><surname>Roelants</surname><given-names>P.</given-names></name><name><surname>Andr&#x000e9;</surname><given-names>F.E.</given-names></name><name><surname>Safary</surname><given-names>A.</given-names></name></person-group><article-title>Reactivity and immunogenicity of bivalent (AC) and tetravalent (ACW135Y) meningococcal vaccines containing O-acetyl-negative or O-acetyl-positive group C polysaccharide</article-title><source>Infect. Immun.</source><year>1983</year><volume>42</volume><fpage>599</fpage><lpage>604</lpage><?supplied-pmid 6417019?><pub-id pub-id-type="pmid">6417019</pub-id></element-citation></ref><ref id="B19-molecules-23-01340"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peltola</surname><given-names>H.</given-names></name><name><surname>Safary</surname><given-names>A.</given-names></name><name><surname>K&#x000e4;yhty</surname><given-names>H.</given-names></name><name><surname>Karanko</surname><given-names>V.</given-names></name><name><surname>Andr&#x000e9;</surname><given-names>F.E.</given-names></name></person-group><article-title>Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides</article-title><source>Pediatrics</source><year>1985</year><volume>76</volume><fpage>91</fpage><lpage>96</lpage><?supplied-pmid 3925430?><pub-id pub-id-type="pmid">3925430</pub-id></element-citation></ref><ref id="B20-molecules-23-01340"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pichichero</surname><given-names>M.</given-names></name><name><surname>Anderson</surname><given-names>P.</given-names></name><name><surname>Gotschlich</surname><given-names>E.</given-names></name><name><surname>Kamm</surname><given-names>J.</given-names></name><name><surname>McMullen</surname><given-names>A.</given-names></name><name><surname>Nielsen</surname><given-names>S.</given-names></name></person-group><article-title>Immunogenicity of O-acetyl-negative and -positive polysaccharide vaccines for infections with <italic>Neisseria meningitidis</italic> group C in infants</article-title><source>J. Infect. Dis.</source><year>1985</year><volume>152</volume><fpage>850</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1093/infdis/152.4.850</pub-id><?supplied-pmid 3930623?><pub-id pub-id-type="pmid">3930623</pub-id></element-citation></ref><ref id="B21-molecules-23-01340"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borrow</surname><given-names>R.</given-names></name><name><surname>Findlow</surname><given-names>J.</given-names></name></person-group><article-title>Prevention of meningococcal serogroup C disease by NeisVac-C</article-title><source>Expert. Rev. Vaccines</source><year>2009</year><volume>8</volume><fpage>265</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1586/14760584.8.3.265</pub-id><?supplied-pmid 19249967?><pub-id pub-id-type="pmid">19249967</pub-id></element-citation></ref><ref id="B22-molecules-23-01340"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fusco</surname><given-names>P.C.</given-names></name><name><surname>Farley</surname><given-names>E.K.</given-names></name><name><surname>Huang</surname><given-names>C.H.</given-names></name><name><surname>Moore</surname><given-names>S.</given-names></name><name><surname>Michon</surname><given-names>F.</given-names></name></person-group><article-title>Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation</article-title><source>Clin. Vaccine Immunol.</source><year>2007</year><volume>14</volume><fpage>577</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1128/CVI.00009-07</pub-id><?supplied-pmid 17376859?><pub-id pub-id-type="pmid">17376859</pub-id></element-citation></ref><ref id="B23-molecules-23-01340"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Longworth</surname><given-names>E.</given-names></name><name><surname>Fernsten</surname><given-names>P.</given-names></name><name><surname>Mininni</surname><given-names>T.L.</given-names></name><name><surname>Vogel</surname><given-names>U.</given-names></name><name><surname>Claus</surname><given-names>H.</given-names></name><name><surname>Gray</surname><given-names>S.</given-names></name><name><surname>Kaczmarski</surname><given-names>E.</given-names></name><name><surname>Borrow</surname><given-names>R.</given-names></name></person-group><article-title>O-acetylation status of the capsular polysaccharides of serogroup Y and W135 meningococci isolated in the UK</article-title><source>FEMS Immunol. Med. Microbiol.</source><year>2002</year><volume>32</volume><fpage>119</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1111/j.1574-695X.2002.tb00543.x</pub-id><?supplied-pmid 11821233?><pub-id pub-id-type="pmid">11821233</pub-id></element-citation></ref><ref id="B24-molecules-23-01340"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taha</surname><given-names>M.K.</given-names></name><name><surname>Achtman</surname><given-names>M.</given-names></name><name><surname>Alonso</surname><given-names>J.M.</given-names></name><name><surname>Greenwood</surname><given-names>B.</given-names></name><name><surname>Ramsey</surname><given-names>M.</given-names></name><name><surname>Fox</surname><given-names>A.</given-names></name><name><surname>Gray</surname><given-names>S.</given-names></name><name><surname>Kaczmarski</surname><given-names>E.</given-names></name></person-group><article-title>Serogroup W135 meningococcal disease in Hajj pilgrims</article-title><source>Lancet</source><year>2000</year><volume>356</volume><fpage>2159</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)03502-9</pub-id><pub-id pub-id-type="pmid">11191548</pub-id></element-citation></ref><ref id="B25-molecules-23-01340"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giardina</surname><given-names>P.C.</given-names></name><name><surname>Longworth</surname><given-names>E.</given-names></name><name><surname>Evans-Johnson</surname><given-names>R.E.</given-names></name><name><surname>Bessette</surname><given-names>M.L.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Borrow</surname><given-names>R.</given-names></name><name><surname>Madore</surname><given-names>D.</given-names></name><name><surname>Fernsten</surname><given-names>P.</given-names></name></person-group><article-title>Analysis of human serum immunoglobulin G against O-acetyl-positive and O-acetyl-negative serogroup W135 meningococcal capsular polysaccharide</article-title><source>Clin. Diagn. Lab. Immunol.</source><year>2005</year><volume>12</volume><fpage>586</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1128/CDLI.12.5.586-592.2005</pub-id><?supplied-pmid 15879019?><pub-id pub-id-type="pmid">15879019</pub-id></element-citation></ref><ref id="B26-molecules-23-01340"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Z.</given-names></name><name><surname>Bohach</surname><given-names>G.A.</given-names></name><name><surname>Shiloach</surname><given-names>J.</given-names></name><name><surname>Norris</surname><given-names>S.E.</given-names></name><name><surname>Freedberg</surname><given-names>D.I.</given-names></name><name><surname>Deobald</surname><given-names>C.</given-names></name><name><surname>Coxon</surname><given-names>B.</given-names></name><name><surname>Robbins</surname><given-names>J.B.</given-names></name><name><surname>Schneerson</surname><given-names>R.</given-names></name></person-group><article-title>Conjugates of group A and W135 capsular polysaccharides of <italic>Neisseria meningitidis</italic> bound to recombinant <italic>Staphylococcus aureus</italic> enterotoxin C1: preparation, physicochemical characterization, and immunological properties in mice</article-title><source>Infect. Immun.</source><year>2005</year><volume>73</volume><fpage>7887</fpage><lpage>7893</lpage><pub-id pub-id-type="doi">10.1128/IAI.73.12.7887-7893.2005</pub-id><?supplied-pmid 16299279?><pub-id pub-id-type="pmid">16299279</pub-id></element-citation></ref><ref id="B27-molecules-23-01340"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gudlavalleti</surname><given-names>S.K.</given-names></name><name><surname>Lee</surname><given-names>C.H.</given-names></name><name><surname>Norris</surname><given-names>S.E.</given-names></name><name><surname>Paul-Satyaseela</surname><given-names>M.</given-names></name><name><surname>Vann</surname><given-names>W.F.</given-names></name><name><surname>Frasch</surname><given-names>C.E.</given-names></name></person-group><article-title>Comparison of <italic>Neisseria meningitidis</italic> serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide</article-title><source>Vaccine</source><year>2007</year><volume>46</volume><fpage>7972</fpage><lpage>7980</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.06.018</pub-id><?supplied-pmid 17936445?><pub-id pub-id-type="pmid">17936445</pub-id></element-citation></ref><ref id="B28-molecules-23-01340"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>A.L.</given-names></name><name><surname>Nizet</surname><given-names>V.</given-names></name><name><surname>Varki</surname><given-names>A.</given-names></name></person-group><article-title>Discovery and characterization of sialic acid O-acetylation in group B <italic>Streptococcus</italic></article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>11123</fpage><lpage>11128</lpage><pub-id pub-id-type="doi">10.1073/pnas.0403010101</pub-id><?supplied-pmid 15263085?><pub-id pub-id-type="pmid">15263085</pub-id></element-citation></ref><ref id="B29-molecules-23-01340"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiman</surname><given-names>S.</given-names></name><name><surname>Uchiyama</surname><given-names>S.</given-names></name><name><surname>Lin</surname><given-names>F.Y.</given-names></name><name><surname>Chaffin</surname><given-names>D.</given-names></name><name><surname>Varki</surname><given-names>A.</given-names></name><name><surname>Nizet</surname><given-names>V.</given-names></name><name><surname>Lewis</surname><given-names>A.L.</given-names></name></person-group><article-title>O-acetylation of sialic acid on group B <italic>Streptococcus</italic> inhibits neutrophil suppression and virulence</article-title><source>Biochem. J.</source><year>2010</year><volume>428</volume><fpage>163</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1042/BJ20100232</pub-id><?supplied-pmid 20334627?><pub-id pub-id-type="pmid">20334627</pub-id></element-citation></ref><ref id="B30-molecules-23-01340"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>V.</given-names></name><name><surname>Berti</surname><given-names>F.</given-names></name></person-group><article-title>Exploring the Group B <italic>Streptococcus</italic> capsular polysaccharides: the structural diversity provides the basis for development of NMR-based identity assays</article-title><source>J. Pharm. Biomed. Anal.</source><year>2014</year><volume>98</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.jpba.2014.05.004</pub-id><?supplied-pmid 24873733?><pub-id pub-id-type="pmid">24873733</pub-id></element-citation></ref><ref id="B31-molecules-23-01340"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pannaraj</surname><given-names>P.S.</given-names></name><name><surname>Edwards</surname><given-names>M.S.</given-names></name><name><surname>Ewing</surname><given-names>K.T.</given-names></name><name><surname>Lewis</surname><given-names>A.L.</given-names></name><name><surname>Rench</surname><given-names>M.A.</given-names></name><name><surname>Baker</surname><given-names>C.J.</given-names></name></person-group><article-title>Group B streptococcal conjugate vaccines elicit functional antibodies independent of strain O-acetylation</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>4452</fpage><lpage>4456</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.05.039</pub-id><?supplied-pmid 19490960?><pub-id pub-id-type="pmid">19490960</pub-id></element-citation></ref><ref id="B32-molecules-23-01340"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carboni</surname><given-names>F.</given-names></name><name><surname>Adamo</surname><given-names>R.</given-names></name><name><surname>Fabbrini</surname><given-names>M.</given-names></name><name><surname>De Ricco</surname><given-names>R.</given-names></name><name><surname>Cattaneo</surname><given-names>V.</given-names></name><name><surname>Brogioni</surname><given-names>B.</given-names></name><name><surname>Veggi</surname><given-names>D.</given-names></name><name><surname>Pinto</surname><given-names>V.</given-names></name><name><surname>Passalacqua</surname><given-names>I.</given-names></name><name><surname>Oldrini</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Structure of a protective epitope of group B <italic>Streptococcus</italic> type III capsular polysaccharide</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2017</year><volume>114</volume><fpage>5017</fpage><lpage>5022</lpage><pub-id pub-id-type="doi">10.1073/pnas.1701885114</pub-id><?supplied-pmid 28439022?><pub-id pub-id-type="pmid">28439022</pub-id></element-citation></ref><ref id="B33-molecules-23-01340"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>M.B.</given-names></name><name><surname>Daoust</surname><given-names>V.</given-names></name><name><surname>Carlo</surname><given-names>D.J.</given-names></name></person-group><article-title>The specific capsular polysaccharide of <italic>Streptococcus pneumoniae</italic> type 9V</article-title><source>Can. J. Biochem.</source><year>1981</year><volume>59</volume><fpage>524</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1139/o81-073</pub-id><?supplied-pmid 6271367?><pub-id pub-id-type="pmid">6271367</pub-id></element-citation></ref><ref id="B34-molecules-23-01340"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNeely</surname><given-names>T.B.</given-names></name><name><surname>Staub</surname><given-names>J.M.</given-names></name><name><surname>Rusk</surname><given-names>C.M.</given-names></name><name><surname>Blum</surname><given-names>M.J.</given-names></name><name><surname>Donnelly</surname><given-names>J.J.</given-names></name></person-group><article-title>Antibody responses to capsular polysaccharide backbone and O-acetate side groups of <italic>Streptococcus pneumoniae</italic> type 9V in humans and rhesus macaques</article-title><source>Infect. Immun.</source><year>1998</year><volume>66</volume><fpage>3705</fpage><lpage>3710</lpage><?supplied-pmid 9673252?><pub-id pub-id-type="pmid">9673252</pub-id></element-citation></ref><ref id="B35-molecules-23-01340"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lugowski</surname><given-names>C.</given-names></name><name><surname>Jennings</surname><given-names>H.J.</given-names></name></person-group><article-title>Structural determination of the capsular polysaccharide of <italic>Streptococcus pneumoniae</italic> type 18C (56)</article-title><source>Carbohydr. Res.</source><year>1984</year><volume>131</volume><fpage>119</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.1016/0008-6215(84)85409-9</pub-id><pub-id pub-id-type="pmid">6488199</pub-id></element-citation></ref><ref id="B36-molecules-23-01340"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>J.</given-names></name><name><surname>Serrano</surname><given-names>Y.</given-names></name><name><surname>Garrido</surname><given-names>R.</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>L.M.</given-names></name><name><surname>Pedroso</surname><given-names>J.</given-names></name><name><surname>Cardoso</surname><given-names>F.</given-names></name><name><surname>Vald&#x000e9;s</surname><given-names>Y.</given-names></name><name><surname>Garc&#x000ed;a</surname><given-names>D.</given-names></name><name><surname>Fern&#x000e1;ndez-Santana</surname><given-names>V.</given-names></name><name><surname>Verez-Bencomo</surname><given-names>V.</given-names></name></person-group><article-title>Relevance of O-acetyl and phosphoglycerol groups for the antigenicity of <italic>Streptococcus pneumoniae</italic> serotype 18C capsular polysaccharide</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>7090</fpage><lpage>7096</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.09.047</pub-id><?supplied-pmid 23036500?><pub-id pub-id-type="pmid">23036500</pub-id></element-citation></ref><ref id="B37-molecules-23-01340"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jarvis</surname><given-names>F.G.</given-names></name><name><surname>Mesenko</surname><given-names>M.T.</given-names></name><name><surname>Martin</surname><given-names>D.G.</given-names></name><name><surname>Perrine</surname><given-names>T.D.</given-names></name></person-group><article-title>Physiochemical properties of the Vi antigen before and after mild alkaline hydrolysis</article-title><source>J. Bacteriol.</source><year>1967</year><volume>94</volume><fpage>1406</fpage><lpage>1410</lpage><?supplied-pmid 6057799?><pub-id pub-id-type="pmid">6057799</pub-id></element-citation></ref><ref id="B38-molecules-23-01340"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szewczyk</surname><given-names>B.</given-names></name><name><surname>Taylor</surname><given-names>A.</given-names></name></person-group><article-title>Immunochemical properties of Vi antigen from <italic>Salmonella</italic> typhi Ty2: Presence of two antigenic determinants</article-title><source>Infect. Immun.</source><year>1980</year><volume>29</volume><fpage>539</fpage><lpage>544</lpage><?supplied-pmid 6163712?><pub-id pub-id-type="pmid">6163712</pub-id></element-citation></ref><ref id="B39-molecules-23-01340"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szu</surname><given-names>S.C.</given-names></name><name><surname>Li</surname><given-names>X.R.</given-names></name><name><surname>Stone</surname><given-names>A.L.</given-names></name><name><surname>Robbins</surname><given-names>J.B.</given-names></name></person-group><article-title>Relation between structure and immunologic properties of the Vi capsular polysaccharide</article-title><source>Infect. Immun.</source><year>1991</year><volume>59</volume><fpage>4555</fpage><lpage>4561</lpage><?supplied-pmid 1937814?><pub-id pub-id-type="pmid">1937814</pub-id></element-citation></ref><ref id="B40-molecules-23-01340"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>C.</given-names></name></person-group><article-title>Revised structures for the capsular polysaccharides from <italic>Staphylococcus aureus</italic> Types 5 and 8 components of novel glycoconjugate vaccines</article-title><source>Carbohydr. Res.</source><year>2005</year><volume>340</volume><fpage>1097</fpage><lpage>1106</lpage><pub-id pub-id-type="doi">10.1016/j.carres.2005.02.001</pub-id><?supplied-pmid 15797125?><pub-id pub-id-type="pmid">15797125</pub-id></element-citation></ref><ref id="B41-molecules-23-01340"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scully</surname><given-names>I.L.</given-names></name><name><surname>Pavliak</surname><given-names>V.</given-names></name><name><surname>Timofeyeva</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Singer</surname><given-names>C.</given-names></name><name><surname>Anderson</surname><given-names>A.S.</given-names></name></person-group><article-title>O-acetylation is essential for functional antibody generation against <italic>Staphylococcus aureus</italic> capsular polysaccharide</article-title><source>Hum. Vaccin. Immunother.</source><year>2018</year><volume>14</volume><fpage>81</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1080/21645515.2017.1386360</pub-id><?supplied-pmid 29182428?><pub-id pub-id-type="pmid">29182428</pub-id></element-citation></ref><ref id="B42-molecules-23-01340"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shinefield</surname><given-names>H.</given-names></name><name><surname>Black</surname><given-names>S.</given-names></name><name><surname>Fattom</surname><given-names>A.</given-names></name><name><surname>Horwith</surname><given-names>G.</given-names></name><name><surname>Rasgon</surname><given-names>S.</given-names></name><name><surname>Ordonez</surname><given-names>J.</given-names></name><name><surname>Yeoh</surname><given-names>H.</given-names></name><name><surname>Law</surname><given-names>D.</given-names></name><name><surname>Robbins</surname><given-names>J.B.</given-names></name><name><surname>Schneerson</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Use of a <italic>Staphylococcus aureus</italic> conjugate vaccine in patients receiving hemodialysis</article-title><source>N. Engl. J. Med.</source><year>2002</year><volume>346</volume><fpage>491</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa011297</pub-id><?supplied-pmid 11844850?><pub-id pub-id-type="pmid">11844850</pub-id></element-citation></ref><ref id="B43-molecules-23-01340"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fattom</surname><given-names>A.I.</given-names></name><name><surname>Horwith</surname><given-names>G.</given-names></name><name><surname>Fuller</surname><given-names>S.</given-names></name><name><surname>Propst</surname><given-names>M.</given-names></name><name><surname>Naso</surname><given-names>R.</given-names></name></person-group><article-title>Development of StaphVAX, a polysaccharide conjugate vaccine against <italic>S. aureus</italic> infection: from the lab bench to phase III clinical trials</article-title><source>Vaccine</source><year>2004</year><volume>22</volume><fpage>880</fpage><lpage>887</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2003.11.034</pub-id><?supplied-pmid 15040941?><pub-id pub-id-type="pmid">15040941</pub-id></element-citation></ref><ref id="B44-molecules-23-01340"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fattom</surname><given-names>A.</given-names></name><name><surname>Matalon</surname><given-names>A.</given-names></name><name><surname>Buerkert</surname><given-names>J.</given-names></name><name><surname>Taylor</surname><given-names>K.</given-names></name><name><surname>Damaso</surname><given-names>S.</given-names></name><name><surname>Boutriau</surname><given-names>D.</given-names></name></person-group><article-title>Efficacy profile of a bivalent <italic>Staphylococcus aureus</italic> glycoconjugated vaccine in adults on hemodialysis: Phase III randomized study</article-title><source>Hum. Vaccin. Immunother.</source><year>2015</year><volume>11</volume><fpage>632</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.4161/hv.34414</pub-id><?supplied-pmid 25483694?><pub-id pub-id-type="pmid">25483694</pub-id></element-citation></ref><ref id="B45-molecules-23-01340"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hestrin</surname><given-names>S.</given-names></name></person-group><article-title>The reaction of acetylcholine and other carboxylic acid derivatives with hydroxylamine, and its analytical application</article-title><source>J. Biol. Chem.</source><year>1949</year><volume>180</volume><fpage>249</fpage><lpage>261</lpage><?supplied-pmid 18133390?><pub-id pub-id-type="pmid">18133390</pub-id></element-citation></ref><ref id="B46-molecules-23-01340"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>C.</given-names></name><name><surname>Lemercinier</surname><given-names>X.</given-names></name></person-group><article-title>Use and validation of NMR assays for the identity and O-acetyl content of capsular polysaccharides from <italic>Neisseria meningitidis</italic> used in vaccine manufacture</article-title><source>J. Pharm. Biomed. Anal.</source><year>2002</year><volume>30</volume><fpage>1233</fpage><lpage>1247</lpage><pub-id pub-id-type="doi">10.1016/S0731-7085(02)00462-4</pub-id><pub-id pub-id-type="pmid">12408914</pub-id></element-citation></ref><ref id="B47-molecules-23-01340"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemercinier</surname><given-names>X.</given-names></name><name><surname>Martinez-Cabrera</surname><given-names>I.</given-names></name><name><surname>Jones</surname><given-names>C.</given-names></name></person-group><article-title>Use and validation of an NMR test for the identity and O-acetyl content of the <italic>Salmonella typhi</italic> Vi capsular polysaccharide vaccine</article-title><source>Biologicals</source><year>2000</year><volume>28</volume><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1006/biol.1999.0238</pub-id><?supplied-pmid 10799051?><pub-id pub-id-type="pmid">10799051</pub-id></element-citation></ref><ref id="B48-molecules-23-01340"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kao</surname><given-names>G.</given-names></name><name><surname>Tsai</surname><given-names>C.M.</given-names></name></person-group><article-title>Quantification of O-acetyl, <italic>N</italic>-acetyl and phosphate groups and determination of the extent of O-acetylation in bacterial vaccine polysaccharides by high-performance anion-exchange chromatography with conductivity detection (HPAEC-CD)</article-title><source>Vaccine</source><year>2004</year><volume>22</volume><fpage>335</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2003.08.008</pub-id><?supplied-pmid 14670314?><pub-id pub-id-type="pmid">14670314</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="molecules-23-01340-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Repeating unit structures of meningococcal serogroup (<bold>a</bold>) A and (<bold>b</bold>) C, with O-acetyl groups inside or outside the saccharide ring, respectively.</p></caption><graphic xlink:href="molecules-23-01340-g001"/></fig><table-wrap id="molecules-23-01340-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">molecules-23-01340-t001_Table 1</object-id><label>Table 1</label><caption><p>Structures of the repeating units containing O-acetyl groups of bacterial polysaccharides antigens of vaccines licensed or tested in clinical trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Polysaccharide</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Repeat Unit </th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>Neisseria meningitidis</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Group A</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02192;6)-&#x003b1;-<sc>d</sc>-Man<italic>p</italic>NAc(3/4OAc)-(1&#x02192;OPO<sub>3</sub>&#x02192;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Group C</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02192;9)-&#x003b1;-<sc>d</sc>-Neu5Ac(7/8OAc)-(2&#x02192;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Group W</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02192;6)-&#x003b1;-<sc>d</sc>-Gal<italic>p</italic>-(1&#x02192;4)-&#x003b1;-<sc>d</sc>-Neu5Ac(7/9OAc)-(2&#x02192;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Group Y</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02192;6)-&#x003b1;-<sc>d</sc>-Glc<italic>p</italic>-(1&#x02192;4)-&#x003b1;-<sc>d</sc>-Neu5Ac(7/9OAc)-(2&#x02192;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Group B <italic>Streptococcus</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Type Ia</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02192;4)-[&#x003b1;-<sc>d</sc>-Neu5Ac(7/8/9OAc)-(2&#x02192;3)-&#x003b2;-<sc>d</sc>-Gal<italic>p</italic>-(1&#x02192;4)-&#x003b2;-<sc>d</sc>-Glc<italic>p</italic>NAc-(1&#x02192;3)]-&#x003b2;-<sc>d</sc>-Galp-(1&#x02192;4)-&#x003b2;-<sc>d</sc>-Glc<italic>p</italic>-(1&#x02192;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Type Ib</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02192;4)-[&#x003b1;-<sc>d</sc>-Neu5Ac(7/8/9OAc)-(2&#x02192;3)-&#x003b2;-<sc>d</sc>-Gal<italic>p</italic>-(1&#x02192;3)-&#x003b2;-<sc>d</sc>-Glc<italic>p</italic>NAc-(1&#x02192;3)]-&#x003b2;-<sc>d</sc>-Gal<italic>p</italic>-(1&#x02192;4)-&#x003b2;-<sc>d</sc>-Glc<italic>p</italic>-(1&#x02192;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Type II</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02192;3)-&#x003b2;-<sc>d</sc>-Glc<italic>p</italic>-(1&#x02192;2)-[&#x003b1;-<sc>d</sc>-Neu5Ac(7/8/9OAc)-(2&#x02192;3)]-&#x003b2;-<sc>d</sc>-Gal<italic>p</italic>-(1&#x02192;4)-&#x003b2;-D-Glc<italic>p</italic>NAc-(1&#x02192;3)-[&#x003b2;-<sc>d</sc>-Gal<italic>p</italic>-(1&#x02192;6)]-&#x003b2;-<sc>d</sc>-Gal<italic>p</italic>-(1&#x02192;4)-&#x003b2;-<sc>d</sc>-Glc<italic>p</italic>-(1&#x02192;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Type III</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02192;6)-[&#x003b1;-<sc>d</sc>-Neu5Ac(7/8/9OAc)-(2&#x02192;3)-&#x003b2;-<sc>d</sc>-Gal<italic>p</italic>-(1&#x02192;4)]-&#x003b2;-<sc>d</sc>-Glc<italic>p</italic>NAc-(1&#x02192;3)]-&#x003b2;-<sc>d</sc>-Gal<italic>p</italic>-(1&#x02192;4)-&#x003b2;-<sc>d</sc>-Glc<italic>p</italic>-(1&#x02192;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Type V</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02192;4)-[&#x003b1;-<sc>d</sc>-Neu5Ac(7/8/9OAc)-(2&#x02192;3)-&#x003b2;-<sc>d</sc>-Gal<italic>p</italic>-(1&#x02192;4)-&#x003b2;-<sc>d</sc>-Glc<italic>p</italic>NAc-(1&#x02192;6)]-&#x003b1;-<sc>d</sc>-Glc<italic>p</italic>-(1&#x02192;4)-[&#x003b2;-<sc>d</sc>-Glc<italic>p</italic>-(1&#x02192;3)]-&#x003b2;-<sc>d</sc>-Gal<italic>p</italic>-(1&#x02192;4)-&#x003b2;-<sc>d</sc>-Glc<italic>p</italic>-(1&#x02192;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Type VI</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02192;6)-[&#x003b1;-<sc>d</sc>-Neu5Ac(7/8/9OAc)-(2&#x02192;3)-&#x003b2;-<sc>d</sc>-Gal<italic>p</italic>-(1&#x02192;3)]-&#x003b2;-<sc>d</sc>-Glc<italic>p</italic>-(1&#x02192;3)-&#x003b2;-<sc>d</sc>-Gal<italic>p</italic>-(1&#x02192;4)-&#x003b2;-<sc>d</sc>-Glc<italic>p</italic>-(1&#x02192;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>Streptococcus pneumoniae</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Type 1</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02192;3)-<sc>d</sc>-AAT-&#x003b1;-Gal<italic>p</italic>-(1&#x02192;4)-&#x003b1;-<sc>d</sc>-Gal<italic>p</italic>A(2/3OAc)-(1&#x02192;3)-&#x003b1;-<sc>d</sc>-Gal<italic>p</italic>A-(1&#x02192;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Type 7F</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02192;6)-[&#x003b2;-<sc>d</sc>-Gal<italic>p</italic>-(1&#x02192;2)]-&#x003b1;-<sc>d</sc>-Gal<italic>p</italic>-(1&#x02192;3)-&#x003b2;-L-Rha<italic>p</italic>(2OAc)-(1&#x02192;4)-&#x003b2;-<sc>d</sc>-Glc<italic>p</italic>-(1&#x02192;3)-[&#x003b1;-<sc>d</sc>-Glc<italic>p</italic>NAc-(1&#x02192;2)-&#x003b1;-L-Rha<italic>p</italic>-(1&#x02192;4)]-&#x003b2;-<sc>d</sc>-Gal<italic>p</italic>NAc-(1&#x02192;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Type 9V</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02192;4)-&#x003b1;-<sc>d</sc>-Glc<italic>p</italic>(2/3OAc)-(1&#x02192;4)-&#x003b1;-<sc>d</sc>-Glc<italic>p</italic>A-(1&#x02192;3)-&#x003b1;-<sc>d</sc>-Gal<italic>p</italic>-(1&#x02192;3)-&#x003b2;-<sc>d</sc>-Man<italic>p</italic>NAc(4/6OAc)-(1&#x02192;4)-&#x003b2;-<sc>d</sc>-Glc<italic>p</italic>-(1&#x02192;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Type 15B</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02192;6)-[&#x003b1;-<sc>d</sc>-Gal<italic>p</italic>(2/3/4/6OAc)-(1&#x02192;2)-[Gro-(2&#x02192;P&#x02192;3)]-&#x003b2;-<sc>d</sc>-Gal<italic>p</italic>-(1&#x02192;2)]-&#x003b2;-<sc>d</sc>-Glc<italic>p</italic>NAc-(1&#x02192;3)-&#x003b2;-<sc>d</sc>-Gal<italic>p</italic>-(1&#x02192;4)-&#x003b2;-<sc>d</sc>-Glc<italic>p</italic>-(1&#x02192;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Type 17F</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02192;3)-&#x003b2;-L-Rha<italic>p</italic>-(1&#x02192;4)-&#x003b2;-<sc>d</sc>-Glc<italic>p</italic>-(1&#x02192;3)-&#x003b1;-<sc>d</sc>-Gal<italic>p</italic>-(1&#x02192;3)-&#x003b2;-L-Rha<italic>p</italic>(2OAc)-(1&#x02192;4)-&#x003b1;-L-Rha<italic>p</italic>-(1&#x02192;2)-<sc>d</sc>-Ara-ol-(1&#x02192;P&#x02192;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Type 18C</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02192;4)-&#x003b2;-<sc>d</sc>-Glc<italic>p</italic>-(1&#x02192;4)-[&#x003b1;-<sc>d</sc>-Glc<italic>p</italic>(6OAc)-(1&#x02192;2)][Gro-(1&#x02192;P&#x02192;3)]-&#x003b2;-<sc>d</sc>-Gal<italic>p</italic>-(1&#x02192;4)-&#x003b1;-<sc>d</sc>-Glc<italic>p</italic>-(1&#x02192;3)-&#x003b2;-L-Rha<italic>p</italic>-(1&#x02192;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Type 22F</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02192;4)-&#x003b2;-<sc>d</sc>-Glc<italic>p</italic>A-(1&#x02192;4)-[&#x003b1;-<sc>d</sc>-Glc<italic>p</italic>-(1&#x02192;3)]-&#x003b2;-L-Rha<italic>p</italic>(2OAc)-(1&#x02192;4)-&#x003b1;-<sc>d</sc>-Glc<italic>p</italic>-(1&#x02192;3)-&#x003b1;-<sc>d</sc>-Gal<italic>f</italic>-(1&#x02192;2)-&#x003b1;-L-Rha<italic>p</italic>-(1&#x02192;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Type 33F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02192;3)-&#x003b2;-<sc>d</sc>-Gal<italic>p</italic>-(1&#x02192;3)-[&#x003b1;-<sc>d</sc>-Gal<italic>p</italic>-(1&#x02192;2)]-&#x003b1;-<sc>d</sc>-Gal<italic>p</italic>-(1&#x02192;3)-&#x003b2;-<sc>d</sc>-Gal<italic>f</italic>-(1&#x02192;3)-&#x003b2;-<sc>d</sc>-Glc<italic>p</italic>-(1&#x02192;5)-&#x003b2;-<sc>d</sc>-Gal<italic>f</italic>(2OAc)-(1&#x02192;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>Salmonella enterica</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>typhi</italic> Vi</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02192;)-&#x003b1;-<sc>d</sc>-Gal<italic>p</italic>NAcA(3OAc)-(1&#x02192;</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>Staphylococcus aureus</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Type 5</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02192;4)-&#x003b2;-<sc>d</sc>-Man<italic>p</italic>NAcA-(1&#x02192;4)-&#x003b1;-L-Fuc<italic>p</italic>NAc(3OAc)-(1&#x02192;3)-&#x003b2;-<sc>d</sc>-Fuc<italic>p</italic>NAc-(1&#x02192;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Type 8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02192;3)-&#x003b2;-<sc>d</sc>-Man<italic>p</italic>NAcA(4OAc)-(1&#x02192;3)-&#x003b1;-L-Fuc<italic>p</italic>NAc-(1&#x02192;3)-&#x003b1;-<sc>d</sc>-Fuc<italic>p</italic>NAc-(1&#x02192;</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: Glc, Glucose; Gal, Galactose; Neu5Ac, <italic>N</italic>-acetyl neuraminic acid (sialic acid); Rha, Rhamnose; GlcNAc, <italic>N</italic>-acetyl Glucosamine; GalNAc, <italic>N</italic>-acetyl Galactosamine; FucNAc, <italic>N</italic>-acetyl Fucosamine; ManNAcA, <italic>N</italic>-acetyl Mannuronic Acid; AAT, 2-acetamido-4-amino-2,4,6-trideoxygalactose; Gro, glycerol, Pne, 2-acetamido-2,6-dideoxytalose; Sug, 2-acetamido-2,6-deoxyhexose-4-ulose; P, phosphate in a phosphodiester linkage.</p></fn></table-wrap-foot></table-wrap></floats-group></article>